VYGR
Voyager Therapeutics, Inc.
Biotechnology · Healthcare · United States
1.72
close · 2026-10-30
value
50
cheaper than peers50
quality
19
stronger fundamentals19
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| earnings yield, 2 years ago | 172.7% | 100 |
| cash flow yield, 2 years ago | 70.4% | 99 |
| price to book | 0.68× | 91 |
| price to sales | 3.08× | 80 |
| cash flow yield, 3 years ago | -14.2% | 37 |
| cash flow yield, 1 year ago | -17.8% | 36 |
| earnings yield, 3 years ago | -70.3% | 25 |
| earnings yield, 1 year ago | -65.7% | 19 |
| earnings yield, latest year | -118.6% | 9 |
| cash flow yield, latest year | -127.4% | 5 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 21.1% | 47 |
| return on equity | -54.1% | 46 |
| operating margin | -833.9% | 24 |
| revenue growth | -39.1% | 21 |
4 of 4 measures available
Facts
| market cap | $106M |
| free cash flow | -$77.3M |
| employees | 141 |
| first trade | 2015-11-11 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-18 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -2.04 | -1.13 | 2.97 | -1.21 |
| free cash flow | -$135.1M | -$18.8M | $74.7M | -$15.0M |
| net income | -$119.7M | -$65.0M | $132.3M | -$46.4M |
| revenue | $40.4M | $80.0M | $250.0M | $40.9M |